Title of article
Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
Author/Authors
Andrew J. Barker، نويسنده , , Keith H. Gibson، نويسنده , , Walter Grundy، نويسنده , , Andrew A. Godfrey، نويسنده , , Jeffrey J. Barlow، نويسنده , , Mark P. Healy، نويسنده , , James R. Woodburn، نويسنده , , Susan E. Ashton، نويسنده , , Brenda J. Curry، نويسنده , , Lynn Scarlett، نويسنده , , Lianne Henthorn، نويسنده , , Laura Richards، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2001
Pages
4
From page
1911
To page
1914
Abstract
This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.
Journal title
Bioorganic & Medicinal Chemistry Letters
Serial Year
2001
Journal title
Bioorganic & Medicinal Chemistry Letters
Record number
791531
Link To Document